Pacira BioSciences Formed European Partnership
The company granted exclusive distribution rights to Molteni Farmaceutici to expand its opioid-sparing pain treatment abroad.
Updated on Oct. 5, 2026 in Business Strategy
Live Poll
Do you trust that pharmaceutical companies prioritize patient access to non-opioid pain management over profits?
Pacira BioSciences has entered a strategic partnership with Molteni Farmaceutici to commercialize its postsurgical pain management drug, EXPAREL, in the United Kingdom and across the European Union. The move tasks the partner with managing regulatory and market access efforts to facilitate an initial launch in four specific countries.
Why it matters
This agreement leverages an established European operator to navigate complex regional regulatory and commercial landscapes for opioid-sparing treatments. The move allows the manufacturer to scale market access for its lead asset without building out an internal European infrastructure from scratch.
Molteni Farmaceutici, an entity with 130 years of operating history, will now oversee the commercialization of EXPAREL across the United Kingdom and the European Union. While the deal involves broad rights, the company recently granted 3,600 stock options and 4,200 restricted stock units to new hires.
The players
Pacira BioSciences
A California-based developer and manufacturer of non-opioid pain management and regenerative health solutions.
Molteni Farmaceutici
A long-standing Italian pharmaceutical company specializing in the development and distribution of pain therapy products.
Locust Walk
A global life sciences transaction firm that provides corporate development and financial advisory services to pharmaceutical companies.
The details
Under the agreement, Pacira BioSciences retains manufacturing responsibilities while offloading the regulatory, marketing, and distribution burdens to Molteni Farmaceutici. The partner plans to prioritize initial launches in Italy, Germany, Austria, and Poland, with Switzerland designated as a key target for future regulatory approval. Locust Walk served as the financial advisor to Pacira during the negotiation of these terms.
Timeline
October 05, 2026: Pacira and Molteni Farmaceutici announced their strategic partnership.
2027: The first commercial sale of EXPAREL is expected.
Market Landscape
This partnership follows the established pattern of specialized manufacturers outsourcing regulatory compliance to local firms to meet the European Medicines Agency's centralized marketing authorization requirements. By relying on an established partner, Pacira avoids the high cost of developing independent regulatory infrastructure in a fractured regional market.
Operators looking to scale internationally should evaluate whether a licensing model with a local partner is more cost-effective than direct expansion. Watch for the 2027 commercial launch date as an indicator of how effectively the partner navigates the regulatory hurdles of the target European countries.
The takeaway
This deal underscores the value of using experienced local partners to circumvent the operational friction of multi-jurisdictional regulatory compliance. Firms should track the 2027 launch to monitor the efficacy of this commercialization model in high-barrier European markets.
Further reading
For more on how firms structure international growth, visit our Business Strategy archive.
Live Poll
Do you trust that pharmaceutical companies prioritize patient access to non-opioid pain management over profits?
